精研科技(300709) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 reached ¥852,002,407.33, representing a 48.53% increase year-over-year[5] - Net profit attributable to shareholders was ¥69,981,713.83, up 73.25% compared to the same period last year[5] - The basic earnings per share increased to ¥0.38, reflecting a growth of 72.73% year-over-year[5] - Total operating revenue for the current period reached ¥2,266,568,807.52, a significant increase of 44% compared to ¥1,575,536,233.56 in the previous period[28] - Net profit for the current period was ¥167,043,118.93, up 74.5% from ¥95,600,806.20 in the previous period[29] - Operating profit increased to ¥173,475,716.45, compared to ¥84,190,864.21 in the previous period, reflecting a growth of 106.5%[29] - Total comprehensive income for the current period was ¥171,307,378.34, compared to ¥94,612,490.08 in the previous period, reflecting an increase of 80.9%[29] - The company reported a diluted earnings per share of 0.81, compared to 0.54 in the previous period, marking a 50% increase[30] Assets and Liabilities - Total assets as of September 30, 2025, amounted to ¥4,134,979,093.29, a 25.76% increase from the end of the previous year[5] - The total liabilities rose to CNY 1,825,890,468.51 from CNY 1,140,230,770.94, indicating an increase of approximately 60.1%[26] - The company's equity attributable to shareholders increased to CNY 2,295,371,004.04 from CNY 2,157,192,319.70, marking a growth of about 6.4%[27] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥249,731,471.58, reflecting a 9.10% increase[12] - The company experienced a 79.16% increase in net cash flow from investing activities, primarily due to changes in financial operations and increased capital expenditures[12] - Cash flow from operating activities generated a net amount of ¥249,731,471.58, compared to ¥228,907,456.04 in the previous period, indicating a growth of 9%[31] - The company reported a significant increase in cash and cash equivalents at the end of the period totaling ¥542,425,409.85, up from ¥401,059,418.43 in the previous period[32] - The company's cash and cash equivalents decreased to CNY 601,278,399.90 from CNY 765,587,552.76, representing a decline of approximately 21.4%[25] Shareholder Information - Total number of common shareholders at the end of the reporting period is 29,181[14] - The largest shareholder, Wang Mingxi, holds 19.43% of shares, totaling 36,161,200 shares[14] - The second-largest shareholder, Huang Yichao, holds 4.90% of shares, totaling 9,110,724 shares[14] - The top ten shareholders hold a significant portion of shares, with the largest holding being 19.43%[14] Research and Development - Research and development expenses for the year-to-date reached ¥214,164,098.30, a 54.02% increase driven by a rise in personnel and material costs[11] - Research and development expenses rose to ¥214,164,098.30, an increase of 54% from ¥139,049,069.70 in the previous period[28] Corporate Governance - The board of directors has been expanded from 7 to 9 members to enhance governance structure, with the addition of one non-independent director and one employee representative director[21] - The company has made strategic moves to enhance its governance and operational efficiency through amendments to its articles of association and board structure[21] Subsidiaries and Incentives - The company established a holding subsidiary, Jiangsu Jingyan Heat Treatment Co., Ltd., on August 2, 2025[19] - The company approved a 2025 restricted stock incentive plan on September 26, 2025[19] - Total restricted shares at the beginning of the period were 37,256,940, with 463,320 shares released during the period[18] - Wang Mingxi's restricted shares remain at 27,120,900, with a transfer limit of 25% annually[17] - Huang Yichao's restricted shares remain at 6,833,043, also with a 25% annual transfer limit[17] - The company has a total of 36,799,704 restricted shares remaining after the period[18] Litigation - The company is involved in ongoing litigation regarding performance compensation related to the acquisition of Antxin, with a retrial application submitted by former shareholders[20] Inventory and Accounts Receivable - Accounts receivable increased by 33.31% to ¥813,184,964.97, primarily due to higher sales revenue[10] - The company reported a significant increase in inventory, which rose to CNY 484,777,958.41 from CNY 396,685,831.07, reflecting a growth of approximately 22.1%[25]